Therapeutic Area | MeSH |
---|---|
neoplasms | D009369 |
signs and symptoms pathological conditions | D013568 |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
EMEND | Merck & Co | N-022023 RX | 2010-11-12 | 1 products, RLD, RS |
FOCINVEZ | SteriScience | N-216686 RX | 2023-08-22 | 1 products, RLD, RS |
FOSAPREPITANT DIMEGLUMINE | Teva | N-210064 RX | 2019-09-05 | 1 products |
Brand Name | Status | Last Update |
---|---|---|
emend | New Drug Application | 2022-05-04 |
focinvez | New Drug Application | 2025-06-12 |
fosaprepitant | ANDA | 2024-12-29 |
fosaprepitant dimeglumine | ANDA | 2024-08-15 |
Expiration | Code | ||
---|---|---|---|
FOSAPREPITANT DIMEGLUMINE, EMEND, MERCK AND CO INC | |||
2025-05-02 | D-186 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Vomiting | D014839 | — | R11.1 | 8 | 22 | 19 | 18 | 15 | 80 |
Nausea | D009325 | — | R11.0 | 4 | 21 | 17 | 14 | 16 | 70 |
Postoperative nausea and vomiting | D020250 | EFO_0004888 | — | 2 | 3 | 4 | 9 | 7 | 24 |
Neoplasms | D009369 | — | C80 | 3 | 3 | 2 | 2 | 5 | 13 |
Lymphoma | D008223 | — | C85.9 | 1 | 2 | — | 1 | 3 | 6 |
Leukemia | D007938 | — | C95 | — | 2 | — | 1 | 2 | 5 |
Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | — | 1 | 1 | 1 | 4 |
Ovarian neoplasms | D010051 | EFO_0003893 | C56 | — | — | — | 1 | 3 | 4 |
Healthy volunteers/patients | — | — | — | 2 | — | — | 1 | — | 3 |
Pruritus | D011537 | — | L29 | 1 | 1 | — | 1 | — | 3 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Depression | D003863 | — | F33.9 | — | — | 9 | — | — | 9 |
Major depressive disorder | D003865 | EFO_0003761 | F22 | — | — | 9 | — | — | 9 |
Depressive disorder | D003866 | EFO_1002014 | F32.A | — | — | 9 | — | — | 9 |
Multiple myeloma | D009101 | — | C90.0 | 1 | 1 | 1 | — | 2 | 5 |
Non-small-cell lung carcinoma | D002289 | — | — | 1 | 2 | 1 | — | 1 | 4 |
Plasma cell neoplasms | D054219 | — | — | — | 1 | 1 | — | 2 | 4 |
Lung neoplasms | D008175 | — | C34.90 | — | 1 | 1 | — | 1 | 3 |
Female genital neoplasms | D005833 | — | — | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Alcoholism | D000437 | EFO_0003829 | F10.1 | — | 3 | — | — | — | 3 |
Carcinoma | D002277 | — | C80.0 | — | 2 | — | — | 1 | 3 |
Myelodysplastic syndromes | D009190 | — | D46 | — | 1 | — | — | 2 | 3 |
Preleukemia | D011289 | — | — | — | 1 | — | — | 2 | 3 |
Sarcoma | D012509 | — | — | — | 1 | — | — | 1 | 2 |
Marijuana abuse | D002189 | EFO_0007191 | F12 | — | 2 | — | — | — | 2 |
Myeloid leukemia acute | D015470 | — | C92.0 | — | 2 | — | — | — | 2 |
Myeloid leukemia | D007951 | — | C92 | — | 2 | — | — | — | 2 |
Renal cell carcinoma | D002292 | EFO_0000376 | — | — | 1 | — | — | — | 1 |
Melanoma | D008545 | — | — | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hiv infections | D015658 | EFO_0000764 | B20 | 3 | — | — | — | — | 3 |
Opioid-related disorders | D009293 | EFO_0005611 | F11 | 2 | — | — | — | — | 2 |
Heroin dependence | D006556 | EFO_0004240 | — | 2 | — | — | — | — | 2 |
Non-hodgkin lymphoma | D008228 | — | C85.9 | 1 | — | — | — | — | 1 |
Substance-related disorders | D019966 | EFO_0003890 | F13 | 1 | — | — | — | — | 1 |
Biological availability | D001682 | — | — | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Gastrointestinal neoplasms | D005770 | — | C26.9 | — | — | — | — | 2 | 2 |
Ovarian epithelial carcinoma | D000077216 | — | — | — | — | — | — | 2 | 2 |
Myeloproliferative disorders | D009196 | — | D47.1 | — | — | — | — | 2 | 2 |
Plasmacytoma | D010954 | — | C90.3 | — | — | — | — | 2 | 2 |
Digestive system neoplasms | D004067 | — | — | — | — | — | — | 1 | 1 |
Cognitive dysfunction | D060825 | — | G31.84 | — | — | — | — | 1 | 1 |
Hypertension | D006973 | EFO_0000537 | I10 | — | — | — | — | 1 | 1 |
Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | — | — | 1 | 1 |
Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | — | — | — | 1 | 1 |
Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | — | — | — | 1 | 1 |
Drug common name | Fosaprepitant dimeglumine |
INN | aprepitant |
Description | Fosaprepitant (Emend for Injection (US), Ivemend (EU)) is an antiemetic medication, administered intravenously. It is a prodrug of aprepitant.
|
Classification | Small molecule |
Drug class | phosphoro-derivatives; tachykinin (neurokinin) receptor antagonists: NK1 receptor antagonists |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.C[C@@H](O[C@H]1OCCN(Cc2nn(P(=O)(O)O)c(=O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1 |
PDB | — |
CAS-ID | 172673-20-0 |
RxCUI | 1731071 |
ChEMBL ID | CHEMBL1201782 |
ChEBI ID | 64311 |
PubChem CID | 219090 |
DrugBank | DB06717 |
UNII ID | 6L8OF9XRDC (ChemIDplus, GSRS) |